Clinical Trial Update: Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for neoadjuvant androgen deprivation with darolutamide and ipatasertib in localized high-risk prostate cancer; study terminated with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Darolutamide (darolutamide)
• ipatasertib (ipatasertib)

Snippet

Sponsor: David VanderWeele | Conditions: Castrate Resistant Prostate Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2023-11-13